Crinetics Pharmaceuticals Inc
CRNX
Crinetics Pharmaceuticals Inc AI Insights
Informational only. Not investment advice.Snapshot
- Working capital of 1.0B covers 3 years of cash burn at current -354M FCF TTM rate, providing extended runway without dilution.[Working Capital]
- R&D of 314M TTM is 204x revenue (1.5M) - pure clinical-stage bet with zero commercial validation yet.[Research and Development TTM]
- P/S ratio of 2,927x vs industry median 4.1x reflects binary outcome pricing on pipeline success.[P/S Ratio]
Watch Triggers
- Free Cash Flow TTM: Burn exceeds -450M/year — Accelerating burn cuts runway below 2 years, forcing dilutive raise at potentially weak terms.
- Total Revenue TTM: Exceeds 50M (milestone/partnership) — First material revenue validates pipeline value and extends runway without equity dilution.
- Research and Development TTM: Drops below 250M — R&D cuts signal pipeline narrowing or capital preservation mode - bearish for growth thesis.
Bull Case
Fortress balance sheet with 1.1B current assets and minimal debt (0.05 D/E) enables full pipeline prosecution without capital constraints through late-stage trials.
R&D intensity (314M vs 1.5M revenue) signals conviction in pipeline - any Phase 3 success could trigger 10x+ revenue inflection.
Bear Case
4.5B market cap on 1.5M revenue (2,927x P/S) prices in blockbuster success - any clinical setback could trigger 50%+ drawdown.
Revenue declined 32% over 3 years while burning 354M annually - no commercial traction despite years of R&D spend.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage CRNX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway extends to 2028+ if burn rate stabilizes, avoiding near-term dilution.
- 1.1B current assets vs 74M current liabilities
- Debt/equity at 0.05 leaves borrowing capacity
- Interest income of 12.5M offsets some burn
Public Strategies Rankings
See how Crinetics Pharmaceuticals Inc ranks across different investment strategies.
Leverage CRNX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
CRNX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$4.59B | — | ||
$4.53B | — | ||
0.00 | — | ||
$1.53M | +47.7% | — | |
$-4.53 | — | ||
-31,130% | -1604.9% | — | |
-27,563% | -815.5% | — | |
$-354.0M | — | ||
-0.44 | -4.2% | — | |
Beta 5Y (Monthly) | unknown | — |
CRNX Dividend History
CRNX Stock Splits
CRNX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
02/27/25 | 12/31/24 | 10-K | |
11/12/24 | 09/30/24 | 10-Q | |
08/08/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
02/28/24 | 12/31/23 | 10-K | |
11/07/23 | 09/30/23 | 10-Q | |
08/08/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
02/28/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/12/22 | 06/30/22 | 10-Q | |
05/12/22 | 03/31/22 | 10-Q | |
03/30/22 | 12/31/21 | 10-K | |
11/05/21 | 09/30/21 | 10-Q | |
08/10/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
03/30/21 | 12/31/20 | 10-K | |
11/06/20 | 09/30/20 | 10-Q | |
08/07/20 | 06/30/20 | 10-Q | |
05/08/20 | 03/31/20 | 10-Q | |
03/09/20 | 12/31/19 | 10-K | |
11/12/19 | 09/30/19 | 10-Q | |
08/13/19 | 06/30/19 | 10-Q | |
05/13/19 | 03/31/19 | 10-Q | |
03/13/19 | 12/31/18 | 10-K | |
11/13/18 | 09/30/18 | 10-Q | |
08/30/18 | 06/30/18 | 10-Q | |
07/18/18 | 03/31/18 | 424B4 | |
07/18/18 | 12/31/17 | 424B4 | |
11/13/18 | 09/30/17 | 10-Q | |
08/30/18 | 06/30/17 | 10-Q | |
07/18/18 | 03/31/17 | 424B4 |